EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

ADNI Private Partners Scientific Board (PPSB) Diversity, Equity, and Inclusion (DE&I) Working Group: A new collaboration that crosses boundaries for industry, academia, and under‐represented patients

Ruth Croney, Emil Fristed, Donna Masterman, Martine Meyer, Pallavi Sachdev, Aparna Vasanthakumar, Christopher J Weber, Theresa Devins

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.14248 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Ruth Croney und 7 weiteren Autor:innen. Beteiligte Einrichtung: Roche Products Ltd, Welwyn Garden City, UK. Hauptthemen laut MEDLINE: Alzheimer Disease, Cooperative Behavior, Drug Industry, Patient Selection. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Alzheimer's Disease Neuroimaging Initiative (ADNI) Private Partners Scientific Board (PPSB) Diversity, Equity, and Inclusion Working Group (DE&I WG) was established to work with the ADNI3 Diversity Task Force to provide an industry perspective on increasing the representation of diverse participants in ADNI3 and to build precompetitive cross‐industry knowledge in engagement and recruitment of under‐represented participants (URPs). In this article, we review and highlight the role and ongoing activities within the ADNI PPSB DE&I WG and provide a cross‐industry perspective on areas where precompetitive collaboration can improve the inclusiveness in clinical trials, drawing on examples from ADNI4. Highlights New collaboration crosses boundaries to allow PPSB DE&I WG members to work together in a preproprietary way. When faced with the same challenges required by FDA combined with a growing prevalence of AD, the DE&I WG has drafted a range of initiatives that may benefit ADNI, AD patients, care partners, and respective companies involved in this work. In order to address the multifactorial problem of successfully enrolling representative populations in clinical trials, it will “take a village” to bring about sustainable changes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCooperative BehaviorDrug IndustryPatient SelectionHumansClinical Trials as TopicNeuroimagingCultural DiversityAcademia

Stichwörter der Autor:innen

Alzheimer's Disease Neuroimaging InitiativeAlzheimer's disease clinical trialsDEIcultural diversity

Autor:innen und Institutionen

  • Roche Products Ltd, Welwyn Garden City, UK.
  • Novoic Inc, London, UK.
  • Prothena Biosciences, Brisbane, California, USA.
  • J&J Innovative Medicine, Raritan, New Jersey, USA.
  • Eisai Inc., Nutley, New Jersey, USA.
  • Abbvie Inc., North Chicago, Illinois, USA.

Zitieren

APA

Croney, R., Fristed, E., Masterman, D., Meyer, M., Sachdev, P., Vasanthakumar, A., Weber, C. J., & Devins, T. (2025). ADNI Private Partners Scientific Board (PPSB) Diversity, Equity, and Inclusion (DE&I) Working Group: A new collaboration that crosses boundaries for industry, academia, and under‐represented patients. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14248

Vancouver

Croney R, Fristed E, Masterman D, Meyer M, Sachdev P, Vasanthakumar A, et al. ADNI Private Partners Scientific Board (PPSB) Diversity, Equity, and Inclusion (DE&I) Working Group: A new collaboration that crosses boundaries for industry, academia, and under‐represented patients. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14248

BibTeX
@article{Croney2025,
  author = {Croney, Ruth and Fristed, Emil and Masterman, Donna and Meyer, Martine and Sachdev, Pallavi and Vasanthakumar, Aparna and Weber, Christopher J and Devins, Theresa},
  title = {ADNI Private Partners Scientific Board (PPSB) Diversity, Equity, and Inclusion (DE&I) Working Group: A new collaboration that crosses boundaries for industry, academia, and under‐represented patients},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.14248}
}
Kostenlos starten →